PGXL Technologies, a global provider in the clinical application of pharmacogenetic and molecular diagnostic testing for personalized medicine, has received a contract to help the National Cancer Institute further the science of early cancer diagnosis through the detection of circulating tumor cells (CTCs). The $300,000 contract was one of four awarded.

PGXL uses DEPArray Technology to work with individual cells. Developed by Silicon Biosystems, DEPArray is the most advanced single-cell-isolation technology in the world. PGXL and Silicon Biosystems will collaborate to develop a way to identify and isolate CTCs that are invisible to conventional technology.  The DEPArray enables clinical researchers and sponsors to obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research.